Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: HAV Clear all
Completed No phase listed Observational

Optimizing HBV Care Cascade Among Foreign-Born in the United States (FOCUS-HBV Study)

NCT05621304
View directory record Official record
Conditions
Chronic Hepatitis B Virus (Hbv)
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 22, 2026, 4:58 AM EDT
Completed No phase listed Observational

Collection of Biological Samples From Patients With Hepatitis-Associated Aplastic Anemia

NCT00050115
View directory record Official record
Conditions
Hepatitis-Associated Aplastic Anemia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 100 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 22, 2026, 4:58 AM EDT
Completed No phase listed Observational Results available

Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection

NCT00388674
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
entecavir, Other anti-HBV medication
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
12,522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
20
States / cities
Coronado, California • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Oct 22, 2026, 4:58 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study

NCT00637520
View directory record Official record
Conditions
Insulin Resistance, Nonalcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1

NCT00850044
View directory record Official record
Conditions
HCV Infection
Interventions
ABT-450, ritonavir, placebo for ABT-450, Placebo for ritonavir
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers

NCT02055365
View directory record Official record
Conditions
Hepatitis B
Interventions
Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 22, 2026, 4:58 AM EDT
Completed No phase listed Observational

Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related Quality

NCT02427204
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants

NCT01215643
View directory record Official record
Conditions
Hepatitis C, Chronic Pain
Interventions
Alisporivir, Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
16
States / cities
La Jolla, California • San Diego, California • Ventura, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 22, 2026, 4:58 AM EDT
Terminated Phase 2 Interventional

FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study

NCT05639543
View directory record Official record
Conditions
Alcohol Associated Hepatitis
Interventions
INT-787, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Fresno, California • Palo Alto, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 22, 2026, 4:58 AM EDT
Terminated Phase 2 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection

NCT00401947
View directory record Official record
Conditions
HCV Infection
Interventions
ACH-0137171
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

NCT00627926
View directory record Official record
Conditions
Hepatitis C
Interventions
Pegylated Interferon Alfa 2a, Telaprevir, Ribavirin, Placebo
Biological · Drug · Other
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Increasing Hepatitis B Screening Among Korean Church Attendees

NCT00760721
View directory record Official record
Conditions
Hepatitis B
Interventions
Educational Small Group Session
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 64 Years
Enrollment
1,123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer

NCT01658878
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Nivolumab, Sorafenib, Ipilimumab, Cabozantinib
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
10
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Pensacola, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 22, 2026, 4:58 AM EDT
Withdrawn No phase listed Observational

SIMpill Medication Dispensing Device in the Treatment of HCV

NCT01691235
View directory record Official record
Conditions
Chronic Hepatitis C Virus
Interventions
SIMpill device
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Oct 22, 2026, 4:58 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

NCT06537414
View directory record Official record
Conditions
Chronic Hepatitis B Virus Infection, Hepatitis B
Interventions
Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
San Francisco, California • San Jose, California • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Phase 1Phase 2 Interventional

Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs

NCT00062816
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
ISIS 14803, peginterferon alfa, ribavirin
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 22, 2026, 4:58 AM EDT
Terminated Phase 4 Interventional Results available

Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients

NCT01592006
View directory record Official record
Conditions
Hepatitis C
Interventions
Peginterferon alfa-2a, Ribavirin, telaprevir
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Oct 22, 2026, 4:58 AM EDT
Terminated Phase 1 Interventional

Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic Cancer

NCT00003434
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
carcinoembryonic antigen peptide 1, hepatitis B antigen peptide
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy

NCT01281839
View directory record Official record
Conditions
Hepatitis C
Interventions
TMC435, Placebo, Peginterferon alpha-2a (PegIFN alpha-2a), Ribavirin (RBV)
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Bakersfield, California • Aurora, Colorado • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 22, 2026, 4:58 AM EDT
Completed No phase listed Observational

Prevention of Recurrent Hepatitis B After Liver Transplantation

NCT00059267
View directory record Official record
Conditions
Hepatitis B, Cirrhosis, Acute Liver Failure, Hepatocellular Carcinoma
Interventions
HBIG, Epivir, Hepsera
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
13 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection

NCT01079806
View directory record Official record
Conditions
Chronic Hepatitis B Virus, Pediatric
Interventions
Entecavir, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
2 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
15
States / cities
San Francisco, California • Hartford, Connecticut • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Phase 2 Interventional

CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

NCT00277238
View directory record Official record
Conditions
Hepatitis, Chronic Active
Interventions
CPG10101, Control
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
14
States / cities
Chicago, Illinois • Indianapolis, Indiana • New Orleans, Louisiana + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Not applicable Interventional Results available

TeleHepC Treatment Trial

NCT04798521
View directory record Official record
Conditions
Hepatitis C
Interventions
Tele-HCV, Community Linkage to Care
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Portland, Oregon • Roseburg, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Fecal Microbiota Transplantation in Pediatric Patients

NCT02108821
View directory record Official record
Conditions
Inflammatory Bowel Diseases (IBD), Crohn's Disease (CD), Ulcerative Colitis (UC)
Interventions
Fecal Microbiota Transplantation (FMT)
Biological
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
2 Years to 22 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 22, 2026, 4:58 AM EDT